** Shares of PTC Therapeutics PTCT.O rise 4.6% to $55.17 in morning trade
** Brokerage J.P.Morgan raises PT to $78 from $72, representing a 47.8% upside to the stock's last close
** "We continue to see PTCT shares as under-appreciated by the Street ahead of two compelling launches in established markets" - J.P. Morgan says
** PTC expects regulatory decisions on co's drugs - sepiapterin to treat the genetic condition phenylketonuria (PKU), and vatiquinone to treat nervous system disorder Friedreich ataxia - this year
** Brokerage says current peak sales estimate of ~$700 mln by 2031 for sepiapterin is "overly conservative"
** Nine of 15 brokerages rate the stock "buy" or higher, four "hold", two "sell" or lower; their median PT is $63.92, according to data compiled by LSEG
** Up to last close, PTCT has risen 71.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。